The Oxford group is using ChADOx1, a viral-vector platform that formed the basis of the Oxford-AstraZeneca COVID-19 vaccine

Existing vaccines may offer some protection against the rare strain now circulating—but the evidence is scant

Nearly 250 people are suspected to have died, and more than 1,100 are infected with the rare strain of Ebola in the DRC and Uganda, though the true spread of the virus is feared…

Three vaccines are being developed to address a rare Ebola strain, which has already claimed nearly 250 lives and poses the risk of becoming the worst outbreak recorded.

Experts have warned that the spread, caused by the Bundibugyo strain of the virus, could surpass the infamous outbreak of Ebola which killed more than 11,000 people between 2014…

Global health groups race to develop a Bundibugyo Ebola vaccine as cases surge in DR Congo and Uganda, with WHO backing a leading rVSV candidate.

There is an effective vaccine for Ebola — but not for the variety spreading rapidly in the Democratic Republic of Congo. Trials are going on for several candidates. How long will…

With the Bundibugyo strain of the disease spreading across the DRC and Uganda, scientists and researchers are trying to find rapid solutions

The Oxford group is using ChADOx1, a viral-vector platform that formed the basis of the Oxford-AstraZeneca COVID-19 vaccine

Researchers aim to stop the Bundibugyo Ebola outbreak in northeastern DRC by fast-tracking a vaccine using a proven viral-vector platform.

Amid the spread of the virus in the Democratic Republic of Congo, vaccine development is being fast-tracked